Oncoprotein DEK as a tissue and urinary biomarker for bladder cancer

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Datta, Antara ^a   Adelson, Martin E ^a   Mogilevkin, Yakov ^a,b,c   Mordechai, Eli ^a   Sidi, Abraham A ^b,c   Trama, Jason P ^a  

^a Medical Diagnostic Laboratories   (United States)

^b WOLFSON MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; ONCOPROTEIN DEK; TUMOR MARKER; UNCLASSIFIED DRUG; DEK PROTEIN, HUMAN; NONHISTONE PROTEIN;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CANCER STAGING; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; MICTURITION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN ISOLATION; SENSITIVITY AND SPECIFICITY; TRANSITIONAL CELL CARCINOMA; URINALYSIS; UROGENITAL TRACT DISEASE; WESTERN BLOTTING; BLADDER TUMOR; GENE EXPRESSION REGULATION; MALE; METABOLISM; MIDDLE AGED; TUMOR CELL LINE; URINE;

AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; CHROMOSOMAL PROTEINS, NON-HISTONE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; ONCOGENE PROTEINS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 79958173560     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-234     Document Type: Article

References (19)

1. Society AC. Cancer Facts and Figures 2010. American Cancer Society 2010, Altanta.
2. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 2009, 374:239-249. 10.1016/S0140-6736(09)60491-8, 19520422.
3. Hurst RE. Does the biomarker search paradigm need re-booting?. BMC Urol 2009, 9:1. 10.1186/1471-2490-9-1, 2654904, 19250539.
4. Van Tilborg AA, Bangma CH, Zwarthoff EC. Bladder cancer biomarkers and their role in surveillance and screening. Int J Urol 2009, 16:23-30. 10.1111/j.1442-2042.2008.02174.x, 19120523.
5. Budman LI, Kassouf W, Steinberg JR. Biomarkers for detection and surveillance of bladder cancer. Can Urol Assoc J 2008, 2:212-221. 2494897, 18682775.
6. Costa VL, Henrique R, Danielsen SA, Duarte-Pereira S, Eknaes M, Skotheim RI, Rodrigues A, Magalhaes JS, Oliveira J, Lothe RA, et al. Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin Cancer Res 16:5842-5851.
7. Jamshidian H, Kor K, Djalali M. Urine concentration of nuclear matrix protein 22 for diagnosis of transitional cell carcinoma of bladder. Urol J 2008, 5:243-247.
8. von Lindern M, Breems D, van Baal S, Adriaansen H, Grosveld G. Characterization of the translocation breakpoint sequences of two DEK-CAN fusion genes present in t(6;9) acute myeloid leukemia and a SET-CAN fusion gene found in a case of acute undifferentiated leukemia. Genes Chromosomes Cancer 1992, 5:227-234. 10.1002/gcc.2870050309, 1384675.
9. Wu Q, Hoffmann MJ, Hartmann FH, Schulz WA. Amplification and overexpression of the ID4 gene at 6p22.3 in bladder cancer. Mol Cancer 2005, 4:16. 10.1186/1476-4598-4-16, 1131921, 15876350.
10. Carro MS, Spiga FM, Quarto M, Di Ninni V, Volorio S, Alcalay M, Muller H. DEK Expression is controlled by E2F and deregulated in diverse tumor types. Cell Cycle 2006, 5:1202-1207. 10.4161/cc.5.11.2801, 16721057.
11. Kroes RA, Jastrow A, McLone MG, Yamamoto H, Colley P, Kersey DS, Yong VW, Mkrdichian E, Cerullo L, Leestma J, Moskal JR. The identification of novel therapeutic targets for the treatment of malignant brain tumors. Cancer Lett 2000, 156:191-198. 10.1016/S0304-3835(00)00462-6, 10880769.
12. Szer IS, Sierakowska H, Szer W. A novel autoantibody to the putative oncoprotein DEK in pauciarticular onset juvenile rheumatoid arthritis. J Rheumatol 1994, 21:2136-2142.
13. Dong X, Michelis MA, Wang J, Bose R, DeLange T, Reeves WH. Autoantibodies to DEK oncoprotein in a patient with systemic lupus erythematosus and sarcoidosis. Arthritis Rheum 1998, 41:1505-1510. 10.1002/1529-0131(199808)41:8<1505::AID-ART23>3.0.CO;2-N, 9704652.
14. Wise-Draper TM, Allen HV, Jones EE, Habash KB, Matsuo H, Wells SI. Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions. Mol Cell Biol 2006, 26:7506-7519. 10.1128/MCB.00430-06, 1636856, 16894028.
15. Wise-Draper TM, Allen HV, Thobe MN, Jones EE, Habash KB, Munger K, Wells SI. The human DEK proto-oncogene is a senescence inhibitor and an upregulated target of high-risk human papillomavirus E7. J Virol 2005, 79:14309-14317. 10.1128/JVI.79.22.14309-14317.2005, 1280217, 16254365.
16. Wise-Draper TM, Mintz-Cole RA, Morris TA, Simpson DS, Wikenheiser-Brokamp KA, Currier MA, Cripe TP, Grosveld GC, Wells SI. Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo. Cancer Res 2009, 69:1792-1799. 10.1158/0008-5472.CAN-08-2304, 2650744, 19223548.
17. Sanchez-Carbayo M, Socci ND, Lozano JJ, Li W, Charytonowicz E, Belbin TJ, Prystowsky MB, Ortiz AR, Childs G, Cordon-Cardo C. Gene discovery in bladder cancer progression using cDNA microarrays. Am J Pathol 2003, 163:505-516. 10.1016/S0002-9440(10)63679-6, 1868230, 12875971.
18. Mor-Vaknin N, Punturieri A, Sitwala K, Faulkner N, Legendre M, Khodadoust MS, Kappes F, Ruth JH, Koch A, Glass D, et al. The DEK nuclear autoantigen is a secreted chemotactic factor. Mol Cell Biol 2006, 26:9484-9496. 10.1128/MCB.01030-06, 1698538, 17030615.
19. Evans AJ, Gallie BL, Jewett MA, Pond GR, Vandezande K, Underwood J, Fradet Y, Lim G, Marrano P, Zielenska M, Squire JA. Defining a 0.5-mb region of genomic gain on chromosome 6p22 in bladder cancer by quantitative-multiplex polymerase chain reaction. Am J Pathol 2004, 164:285-293. 10.1016/S0002-9440(10)63118-5, 1602217, 14695341.